{"id":41637,"date":"2021-11-30T07:23:26","date_gmt":"2021-11-30T07:23:26","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=41637"},"modified":"2021-11-30T14:44:10","modified_gmt":"2021-11-30T14:44:10","slug":"colchicine-no-clinical-benefits-against-covid-19-in-pooled-analysis-of-rcts","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/41637","title":{"rendered":"Colchicine: no clinical benefits against COVID-19 in pooled analysis of RCTs"},"content":{"rendered":"
\n

Simon Collins, HIV i-Base<\/strong><\/p>\n<\/div>\n

\n

Results from a pooled analysis of available studies reports from using the anti-inflammatory gout medication colchicine against clinical risks from COVID-19, including hospitalisation or mortality.<\/span><\/strong><\/p>\n<\/div>\n

\n

It also reported an increased risk of side effects, including diarrhoea. [1]<\/span><\/p>\n<\/div>\n

\n

The analysis included results from <\/span>six randomised controlled trials involving more than 16,000 participants. Level of evidence for the GRADE analysis was generally moderate.<\/p>\n<\/div>\n

\n

However, the six studies used different designs and doses and 5\/6 studies were in more advanced infection when participants were already hospitalised. This is not discussed in the paper.<\/p>\n<\/div>\n

\n

The single study in early COVID-19 was a Canadian study that in January 2021, reported benefits at reducing hospitalisation (Tardif et al). However, this study discontinued recruiting before full enrolment (at approximately 75%) after a positive signal of benefit. At this stage, by ITT analysis, the benefit was not statistically significant. [2]<\/p>\n<\/div>\n

\n

References<\/span><\/p>\n<\/div>\n

\n
    \n
  1. Mehta KG et al. Efficacy and safety of colchicine in COVID-19: a meta-analysis of randomised controlled trials. doi: 10.1136\/rmdopen-2021-001746<\/span>.
    \nhttps:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2021-001746<\/a><\/li>\n
  2. Oral colchicine reduces hospitalisation in international randomised phase 3 outpatient study. HTB (January 2021).
    \n    https:\/\/i-base.info\/htb\/39776<\/a><\/li>\n<\/ol>\n

    This report was firt posted on 24 November 2021.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    Simon Collins, HIV i-Base Results from a pooled analysis of available studies reports from using the anti-inflammatory gout medication colchicine against clinical risks from COVID-19, including hospitalisation or mortality. It also reported an increased risk of side effects, including diarrhoea. …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[283,278],"tags":[],"class_list":["post-41637","post","type-post","status-publish","format-standard","hentry","category-covid-19-investigational-drugs","category-covid-19"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/41637","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=41637"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/41637\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=41637"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=41637"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=41637"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}